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Abstract
The 2016 World Health Organization classification introduced a number of genes with
somatic mutations and a category for germline predisposition syndromes in myeloid neo-
plasms. We have designed a comprehensive next-generation sequencing assay to detect
somatic mutations, translocations, and germline mutations in a single assay and have evalu-
ated its clinical utility in patients with myeloid neoplasms. Extensive and specified bioinfor-
matics analyses were undertaken to detect single nucleotide variations, FLT3 internal
tandem duplication, genic copy number variations, and chromosomal copy number varia-
tions. This enabled us to maximize the clinical utility of the assay, and we concluded that, as
a single assay, it can be a good supplement for many conventional tests, including Sanger
sequencing, RT-PCR, and cytogenetics. Of note, we found that 8.4–11.6% of patients with
acute myeloid leukemia and 12.9% of patients with myeloproliferative neoplasms had germ-
line mutations, and most were heterozygous carriers for autosomal recessive marrow failure
syndromes. These patients often did not respond to standard chemotherapy, suggesting
that germline predisposition may have distinct and significant clinical implications.
Introduction
Whole genome and exome studies have revealed a wide genetic heterogeneity in myeloid neo-
plasm by discovering oncogenic mutations in hundreds of genes [1]. Embracing this advance-
ment in knowledge, revised 2016 World Health Organization (WHO) classification has
incorporated or suggested a number of genes required for the diagnosis and risk stratification
of myeloid neoplasms [2]. Of note, the WHO 2016 classification has added a section on mye-
loid neoplasms with a germline predisposition for use in classifying cases with an inherited
defect in genes for platelet disorder, bone marrow failure syndrome (MFS), Noonan syn-
drome, telomere biology disorder, and many others: there are more than a hundred genes
responsible for this category.
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Many clinical laboratories are adopting next-generation sequencing (NGS) panel testing in
diagnosis of patients with acute leukemia. Using NGS testing, a number of mutations that are
critical in diagnosis and risk stratification can be identified in a relatively short time, compared
to conventional tests, although conventional testing methods, such as fluorescence in situ
hybridization (FISH) and RT-PCR, still have their strengths in detecting various type of
genetic variations, including structural variations. As application of NGS testing has broad-
ened discoveries of unexpected genetic variations, comprehensive understanding of disease is
becoming possible, with which better prognostication and treatment choices are expected.
With the increasing demand for an ability to examine a variety of genes, we have designed a
comprehensive genetic test using NGS for acute myeloid leukemia (AML) and other myeloid
neoplasms, reflecting changes in the new WHO 2016 classification, that covers genes for most
germline predisposition syndromes and intronic hotpots of 12 recurrently translocated genes.
To maximize the utility of the assay, we conducted extensive bioinformatics analyses: one use-
ful approach was to recycle off-target data to analyze whole-genome copy number status,
which could supplement conventional cytogenetics. We have deemed that our comprehensive
test, as a single assay, could be a good substitute or supplement for many conventional tests.
Utilizing our newly developed test, we were able to discover a high frequency of germline
mutations in cancer predisposition genes. Patients with these mutations exhibited different
clinical characteristics suggesting that germline predisposition has distinct and significant clin-
ical implications.
Materials and methods
Patients and samples
Bone marrow aspirates of patients diagnosed with AML, myelodysplastic syndrome (MDS),
and myeloproliferative neoplasm (MPN) in our center between July 2016 and May 2017 were
obtained after getting informed consent for genetic study from each patient. The current study
was approved by Severance Hospital Institutional Review Board (4-2016-0869).
Conventional laboratory tests
Conventional G-banding karyotyping and FISH were performed using heparinized bone
marrow aspirate following standard protocols. FISH for BCR-ABL1, PML-RARA, RUNX1-
RUNX1T1, KMT2A, and CBFB-MYH11 were performed using Vysis probes (Abbott Molecu-
lar, Abbott Park, IL, USA). To identify recurrent translocations, RT-PCR was performed using
a HemaVision kit (DNA Technology, Aarhus, Denmark) according to the manufacturer’s
instructions. For FLT3 internal tandem duplication (ITD) detection, PCR amplification and
fragment analysis were conducted using a 3130 DNA Analyzer (Applied Biosystems, Foster
City, CA, USA) and Gene-Mapper 3.2 software (Applied Biosystems). Sanger sequencing was
performed using the BigDye Terminator Cycle Sequencing Ready Reaction Kit on an ABI
Prism 3730 Genetic Analyzer (Applied Biosystems).
Gene panel and probe design
After reviewing the WHO 2016 classification and other related literature, a total of 215 genes
were included in the panel (S1 Table). They include 116 genes frequently mutated or rear-
ranged in myeloid neoplasm and 113 genes in which variations are known to predispose mye-
loid neoplasm, with 14 genes overlapping. All coding exons were included. Intronic regions
with reported pathogenic mutations were retrieved from the ClinVar database (version
20170502) and HGMD professional (version 16.02) and were added to the target regions. To
Myeloid NGS panel testing
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detect gene rearrangements at the DNA level, we included intronic breakpoint hotspots for 12
recurrently translocated genes to the target regions: BCR, FGFR1, FUS, JAK2, KMT2A,
MYH11, NUP214, PDGFRA, PDGFRB, RARA, RBM15, and RUNX1 (S2 Table).
Complementary RNA probes, approximately 120 bp in length, were designed to 2× tile
across target genes and were synthesized (Celemics, Seoul, Korea). Probes for 18 core genes
and regions with high mutation frequency and/or clinical implications, such as NPM1 exon 11
and FLT3 exons 14 and 15, were designed to have an ultra-high sequencing depth (S3 Table).
Repeat masking was not performed to avoid the possibility of missing translocations that
occurred in repeat areas. In total, the size of the capture region was estimated to be 0.8 Mb.
Capture and sequencing
Genomic DNA was extracted from bone marrow using a QIAamp DNA Blood Mini Kit
(Qiagen, Venlo, The Netherlands). Approximately 1.5 μg of genomic DNA was fragmented to
segments between 150 and 250 bp in length using the Bioruptor Pico Sonication System (Diag-
enode, Belgium). The resulting DNA was then end-repaired and ligated to Illumina adapters
(Illumina, San Diego, CA, USA). Sequence indexes were added to the samples to allow all sam-
ples to be sequenced in a single flow cell. Small fragments of ~100 bp and unligated adapters
were removed using the AMPure purification system (Agencourt Bioscience, Beverly, MA,
USA). Sequencing libraries were then hybridized with the capture probes. Streptavidin-coated
paramagnetic beads were used to remove unbound DNA. The captured DNA was finally
eluted from the magnetic beads by digestion of the cRNA capture probes and purified. The
enriched DNA was then amplified using universal primers targeting the paired-end adapters,
clusters were generated, and DNA was sequenced on a NextSeq 550 instrument (Illumina)
with 2×151 bp reads. All procedures were performed according to the manufacturer’s
instructions.
Data analysis
The analysis flow and bioinformatic tools used are depicted in Fig 1. Reads were aligned to
human genomic reference sequences (GRCh37) using the Burrows-Wheeler alignment
(BWA) tool (version 0.7.12)[3]. To identify single nucleotide variations (SNV) and insertion
and deletions (indels), HaplotypeCaller and MuTect2 in the GATK package (3.8–0) and VarS-
can2 (2.4.0) were used, and the results of the three algorithms were compared and merged [4–
6]. A split-read analysis was conducted using Pindel (version 0.2.0) to detect large indels, espe-
cially FLT3 ITDs [7]. Translocations were identified using BreakDancer (1.3.6) and Delly2
(version 0.7.7) [8,9]. All mutations were annotated using ANNOVAR and VEP (87) software
[10,11]. Annotated variants were further evaluated using the following filtering strategy: 1) var-
iants classified as benign and likely benign according to the Standards and Guidelines by the
American College of Medical Genetics and Genomics (ACMG) and the Association for Molec-
ular Pathology (AMP) [12], with a scoring algorithm implemented in the DxSeq Analyzer
(Dxome, Seoul, Korea), were excluded; 2) variants with> 0.01 population frequency judged
using the Exome Aggregation Consortium (ExAC) database were eliminated; 3) variants pres-
ent as a somatic mutation in the COSMIC database of cancer mutations were included; and 4)
known mutations of recurrently mutated genes in myeloid neoplasms were included. Most
missense variants with unknown significance were discarded, and nonsense, frameshift, or
splice site variants were included when the known mechanism of the mutation was loss-of-
function. All of the variants were manually verified using the Integrative Genomic Viewer
[13].
Myeloid NGS panel testing
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An R package, ExomeDepth (version 1.1.10), was used to detect genic or exonic level copy
number variations (CNV) in target regions, followed by visualization using a base-level read
depth normalization algorithm implemented in the DxSeq Analyzer (Dxome)[14]. The R
package CopywriteR (version 2.9.0) was used with a 1 Mb window option for off-target analy-
sis and whole chromosomal CNV detection [15].
Confirmation with other methods
For 34 cases of AML and 16 cases of MPN, Sanger sequencing was additionally performed for
11 genes with a high mutation frequency: these included ASXL1, CEBPA, CALR, DNMT3A,
FLT3, IDH1, IDH2, JAK2, KIT, MPL, and NPM1. Highly probable CNVs noted upon visual
inspection were further confirmed by multiplex ligation-dependent probe amplification
(MLPA) if probes were available from MRC-Holland (Amsterdam, The Netherlands). Patho-
genic mutations in germline predisposition genes were confirmed by the Sanger sequencing of
buccal swab or peripheral blood samples at complete remission.
Results
Patients and diagnosis
A total of 129 patients comprising 57 females and 72 males (median age of 56 years; ranging
from 6 months to 85 years) were enrolled. Ninety-five were diagnosed with AML, 31 were
diagnosed with MPN, and three were diagnosed with MDS (Table 1).
NGS statistics
On average, 14.36 ± 3.05 million reads were generated per sample, with approximately 98%
(13.97 ± 3.31 million reads) being mapped to the human reference genome (GRCh37). Mean
coverage within target regions was 670×, and for every sample, more than 99.7% of the target
region was covered with at least 30 reads.
Fig 1. NGS data analysis flow and bioinformatics tools.
https://doi.org/10.1371/journal.pone.0212228.g001
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Sequence variations
After filtering out benign or likely benign polymorphisms, we identified 280 variants involving
65 genes (Fig 2 and S4 Table). At least one variant was detected in 119 patients, and on average,
2.4 variants were detected per patient. For 34 AML and 16 MPN patients, 11 frequently
mutated genes were sequenced by NGS and Sanger sequencing all in perfect agreement (S5
Table).
We observed a relatively high frequency of mutations in genes involved in signal transduc-
tion and epigenetic regulation. In addition to FLT3 and NPM1 mutations, we found a high fre-
quency of ASXL1 mutations in AML cases, somewhat more frequent than what has been
reported previously [1,16–18]. Among 14 patients with CEBPA mutation, biallelic mutations
were found in nine patients. In MPN patients, JAK2 V617F mutation was most common, fol-
lowed by mutations in ASXL1, MPL, and TET2. We found a concurrence among DNMT3A
and NPM1 mutations and FLT3 ITD as previously reported (Fig 2) [19]. Mutations in epige-
netic modifiers, including DNMT3A, ASXL1, IDH1/2, and TET2, tended to occur with other
mutations, in line with the hypothesis that mutations in these genes are early events [20–24].
NPM1 mutations were often accompanied with mutations in these epigenetic genes [24] and
were associated with mutations in NRAS codon 12 and codon 13.[24] Mutations in genes of
the same pathway rarely coexisted. WT1 mutations were more common in patients younger
than 60 years and were less likely to coexist with DNMT3A, ASXL1, IDH1, and IDH2 muta-
tions. Also, multiple subclones were commonly observed, in line with previous observations
[16,17,25].
Table 1. WHO classification of cases enrolled in this study.
WHO classification n
Myeloproliferative neoplasms (MPN)
Polycythemia vera 5
Primary myelofibrosis 8
Essential thrombocythemia 18
Myelodysplastic syndrome (MDS)
Refractory anemia with excess blasts 3
Acute myeloid leukemia (AML) with recurrent genetic abnormalities
AML with t(8;21)(q22;q22); RUNX1-RUNX1T1 9
AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 3
APL with t(15;17)(q22;q12); PML-RARA 9
AML with t(9;11)(p22;q23); MLLT3-KMT2A 1
AML with mutated NPM1 14
AML with biallelic mutations of CEBPA 8
AML with myelodysplasia-related changes 14
Therapy-related myeloid neoplasms 1
AML, NOS
AML without maturation 3
AML with maturation 27
Acute myelomonocytic leukemia 3
Acute monoblastic/monocytic leukemia 2
Myeloid proliferations related to Down syndrome 1
Total 129
https://doi.org/10.1371/journal.pone.0212228.t001
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FLT3 ITD
By conventional PCR and fragment analysis, 17 cases were found to have FLT3 ITD mutation.
GATK, an algorithm optimized for the detection of SNVs, could detect the mutation in only 8
(47%) of 17 positive cases. Pindel, an algorithm based on split-read identification and opti-
mized for indel detection, could detect mutations in all cases. Table 2 summarizes FLT3 ITD
results with duplication size and allele frequency. Insertion sites were exclusively located in
exon 14, a juxtamembrane domain, with inserted sequences of varying sizes (24–201 bp) and
allele frequency (2.3–30.3%).
Genic CNV. CNV analysis at the genic or exonic level was performed by comparison of
read depths in each sample to those in other samples in the same batch. Calling of abnormal
Fig 2. Characterization of mutations. (A) Mutations classified according to the categories of gene functions. (B) Circos diagram
showing co-occurrence and mutual exclusivity of mutations.
https://doi.org/10.1371/journal.pone.0212228.g002
Table 2. Identification of FLT3- ITD by different NGS algorithms.
ID PCR-fragment analysis NGS, GATK NGS, Pindel
Mutation Duplication size (bp) Allele frequency
P1 Detected - Detected 183 0.07
P5 Detected - Detected 39 0.22
P6 Detected - Detected 120 0.02
P7 Detected Detected Detected 42 0.12
P8 Detected - Detected 84 0.04
P9 Detected Detected Detected 66 0.12
P10 Detected - Detected 201 0.18
P14 Detected Detected Detected 54 0.34
P41 Detected - Detected 87 0.19
P77 Detected - Detected 24 0.15
P84 Detected - Detected 96 0.03
P91 Detected Detected Detected 57 0.15
P93 Detected Detected Detected 48 0.10
P95 Detected - Detected 138 0.10
P115 Detected Detected Detected 54 0.30
P128 Detected Detected Detected 43 0.17
P130 Detected Detected Detected 69 0.26
https://doi.org/10.1371/journal.pone.0212228.t002
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copy numbers were done using R package Exomedepth [14], while illustration of depth in
comparison with other samples was done using DxSeq analyzer (Dxome). Fig 3A shows an
example of a KMT2A (MLL) partial tandem duplication (PTD). The deletion or duplication of
exons or whole genes were detected in 19 patients, and in those genes with an available MLPA
kit, the CNVs were confirmed to be true (Table 3). The results were found to be reliable, espe-
cially when changes appeared in consecutive exons, although deletion or duplication of a single
exon was also confirmed to be true positive (e.g., PALB2 exon 8 deletion in P13).
Chromosomal CNV
Genome wide copy number status was assessed using R package CopywriteR [15]. Because the
on-target capture efficiency was about 40% on average, CNV at the whole genome level could
be estimated with the remaining off-target reads. After excluding 25 cases with incomplete
cytogenetic information, such as no mitotic cells, complex karyotypes, and balanced transloca-
tions, which intrinsically cannot be detected by NGS analysis, we estimated the concordance
rate between cytogenetics and NGS to be about 87.5% (91/104) (S6 Table). With higher resolu-
tion than conventional karyotyping, NGS analysis could detect small interstitial deletions,
Fig 3. Visualization of copy number analyses. (A) CNV analysis at the genic or exonic level was performed by
comparison of read depths at base level. An example of a KMT2A (MLL)-partial tandem duplication is illustrated. (B)
CNV at the whole genome level was estimated by off-target read analysis. Cryptic deletion on 7q was identified, and
the case could be reclassified as AML with myelodysplasia-related changes after NGS analysis.
https://doi.org/10.1371/journal.pone.0212228.g003
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except for abnormalities in minor clones. Fig 3 shows exemplary cases that had a cryptic dele-
tion in 5q or 7q and could be reclassified as AML with myelodysplasia-related changes after
the NGS analysis. Chromosome analysis could not be completed in some cases because no
mitotic cells were obtainable; therefore, NGS analysis could help in acquiring karyotype
information.
Detection of translocations at the DNA level
Gene rearrangements were evaluated in sequencing reads of intronic hotspots using Break-
Dancer and the Delly algorithm. In 26 patients with AML, the recurrent translocations
BCR-ABL1, RUNX1-RUNX1T1, CBFB-MYH11, PML-RARA, SET-NUP24, ZBTB16-RARA,
KMT2A-MLLT3, and FUS-ERG were identified by RT-PCR. Among those gene fusions, 3
(11.5%) and 17 (65.4%) cases were identified by BreakDancer and Delly, respectively (Table 4
and Fig 4).
Germline predisposition
After examining 113 cancer predisposition genes, we could identify definite or highly probable
germline mutations in nine genes, including ATM, BLM, BRCA2, DDX41, FANCA, PALB2,
RAD51, SBDS, and WRAP53. Among 95 patients with AML, eight were confirmed to have
pathogenic mutations in germline samples and three had pathogenic mutations in genes
where almost only germline mutations are implicated in AML (Table 5). In total, we
Table 3. Genic and exonic CNVs identified.
ID Gene Region Deletion/duplication MLPA
P4 KMT2A Exons 3–6 PTD Confirmed
P17 KMT2A Exons 2–8 PTD Confirmed
P78 KMT2A Exons 2–8 PTD Confirmed
P130 KMT2A Exons 3–6 PTD ND
P133 KMT2A Exons 2–8 PTD ND
P13 PALB2 Exon 8 Deletion Confirmed
P9 ABL1 Whole gene Deletion ND
P16 WT1 Exons 1–9 Deletion Confirmed
MYC Whole gene Deletion ND
P12 PML Exons 6–8 Deletion ND
P22 NF1 Whole gene Deletion Confirmed
P26 EZH2 Whole gene Deletion Confirmed
KMT2C Whole gene Deletion ND
P34 CSF2RA Whole gene Deletion Confirmed
P36 CBL Exons 8–9 Deletion ND
P42 RUNX1 Exons 2–7 Duplication ND
P47 CSF2RA Whole gene Deletion Confirmed
P52 NF1 Whole gene Duplication Confirmed
P57 RIT1 Exons 1–3 Duplication ND
P60 TET2 Whole gene Deletion ND
P118 TP53 Whole gene Deletion ND
SUZ12 Whole gene Deletion ND
PTD, partial tandem duplication; MLPA, Multiplex ligation-dependent probe amplification; ND, not done
https://doi.org/10.1371/journal.pone.0212228.t003
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determined that 8.4–11.6% of patients with AML harbored germline mutations. Most patients
were monoallelic mutation carriers for autosomal recessive MFSs, including Fanconi anemia,
dyskeratosis congenita, Bloom syndrome, and ataxia-telangiectasia. Two patients harbored
heterozygous mutations in DDX41, which is known as one of the frequently mutated germline
predisposition genes in late onset MDS or AML. Two patients shared the same mutation,
A500Cfs�9, which is reported only in Asians [26,27]. Among nine patients whose bone mar-
row studies were performed after induction chemotherapy, only five of them reached complete
remission, suggesting a possible association between those mutations and a poor treatment
response.
Among 31 patients with MPN, four (12.9%) were thought to have germline mutations in
genes for Fanconi anemia and Shwachman-Diamond syndrome. Contrary to our expectations,
older adult patients also had a high frequency of germline mutations.
More than half (8/15; 53.3%) of our cases were mutation carriers of genes for Fanconi ane-
mia, and among the genes, BRCA2 and PALB2 are known to be associated with other cancers,
including breast and ovarian cancers. One case was a mutation carrier of ATM, which is also
associated with risks for other solid cancers. These patients could benefit from genetic counsel-
ing and preventive monitoring and risk reduction for other cancers.
Table 4. Detection of recurrent translocations in DNA samples by different NGS algorithms.
ID Chromosome RT-PCR NGS, BreakDancer NGS, Delly
P9 46,XY[20] SET-NUP214 Detected Detected
P11 45,X,-Y,t(8;21)(q22;q22)[20]/46,XY[4] RUNX1-RUNX1T1 - Detected
P12 46,XY,t(15;17)(q24;q21)[7] PML-RARA - Detected
P13 46,XX,t(15;17)(q24;q21)[19]/46,XX[1] PML-RARA - -
P14 47,XX,+8,t(15;17)(q24;q21)[20] PML-RARA - Detected
P15 46,XY,t(11;17)(q23;q21)[3]/47,sl,+8[7]/46,XY[10] ZBTB16-RARA - -
p18 46,XX[20] KMT2A-MLLT3 - -
P19 Not tested CBFB-MYH11 - -
P20 46,XX,+del(1)(p13),-16,der(21)t(16;21)(p11;q22) FUS-ERG - Detected
P23 45,X,-Y,t(8;21)(q22;q22)[20] RUNX1-RUNX1T1 - Detected
P26 47,XX,+8,inv(16)(p13q22)[22] CBFB-MYH11 Detected Detected
P27 No mitotic cells RUNX1-RUNX1T1 - Detected
P34 46,XY[20] RUNX1-RUNX1T1 - Detected
P36 46,XX,inv(16)(p13q22)[19]/46,XX[9] CBFB-MYH11 Detected Detected
P43 46,XY,del(9)(q22)[6]/46,XY[17] RUNX1-RUNX1T1 - Detected
P45 46,XX,t(15;17)(q24;q21)[22]/46,XX[2] PML-RARA - Detected
P47 45,X,-Y,t(8;21)(q22;q22)[21] RUNX1-RUNX1T1 - Detected
P72 46,XX,t(8;21)(q22;q22)[20] RUNX1-RUNX1T1 - -
P73 46,XX,t(8;21)(q22;q22)[20] RUNX1-RUNX1T1 - Detected
P82 46,XY,t(15;17)(q24;q21)[5]/46,idem,del(7)(q22)[7]/46,XY[1] PML-RARA - Detected
P83 46,XY,t(15;17)(q24;q21)[16]/46,XY[4] PML-RARA - Detected
P84 46,XY,t(15;17)(q24;q21)[16]/46,XY[4] PML-RARA - Detected
P117 46,XX[20] PML-RARA - -
P123 46,XY,t(8;21)(q23;q22)[11]/46,XY[9] RUNX1-ZFPM2 - -
P131 46,XX,t(15;17)(q24;q21)[20] PML-RARA - -
P134 47,XX,+8,t(10;11)(p13;q21)[20] KMT2A-MLLT10 - -
https://doi.org/10.1371/journal.pone.0212228.t004
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Discussion
Owing to the diverse types of genetic abnormalities, conventional workup for AML and other
myeloid neoplasms requires a variety of methods, including chromosome analysis, FISH,
RT-PCR, real-time PCR, fluorescence PCR and fragment analysis, MLPA, and Sanger
sequencing. Recent NGS technologies are able to obtain a great deal of genomic information
from a single assay. Moreover, in addition to detection of sequence variations, we believe that
a single NGS assay has the potential to replace many conventional assays. By adopting various
bioinformatics algorithms, we validated that extensive analyses on NGS data can yield results
comparable to many conventional molecular and cytogenetic assays. Our custom NGS panel
consists of 215 genes. Although recurrently mutated genes are limited in number, we added a
number of genes associated with cancer predisposition to the panel: in WHO diagnostic crite-
ria, more than 40 genes are listed in association with MFS [28]. We composed the large panel
in an attempt to maximize the possibility of mutation detection in germline predisposition
genes.
FLT3 ITD is a duplication of a juxtamembrane domain of the FLT3 gene, and the mutations
are reported to range in size from 3 to more than 400 bp. Detection of FLT3 ITD is essential in
the management of AML due to its high impact on prognostic stratification and treatment
decision [29]. Standard variant detection tools for NGS data, such as GATK, are usually
designed to detect SNVs and thus can miss large size genetic alterations [30]. Therefore, we
adopted the Pindel algorithm, which is based on a split-read analysis and optimized specifically
for detecting large insertions or deletions [7], and were able to confirm its excellent
performance.
Detecting genic or exonic level CNVs is still challenging, and different algorithms have
their own strengths and weaknesses [30]. We adopted the ExomeDepth algorithm, which is
highly sensitive, even in detecting small deletions or duplications, but produces more false-
Fig 4. With capture probes targeting intronic breakpoints, DNA sequencing could detect recurrent translocations.
An example of a case with PML-RARA fusion. The other part (mate) of each paired-end read is located in different
genes in different chromosomes.
https://doi.org/10.1371/journal.pone.0212228.g004
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positives [14]. This was further validated using the DxSeq Analyzer; the variability of read
depth in each base position was normalized and illustrated. With visual inspection, CNV calls
in regions with high variability among samples in the same batch or without neat signals were
assumed more likely to be false-positives. The validity of our approach was further confirmed
using MLPA testing. The clinical utility of CNV analysis was evident in detecting KMT2A
PTD, which is associated with poor prognosis, but its detection is tricky because of the need to
amplify common rearrangement breakpoints using RNA samples [31,32]. Without additional
testing, we could easily detect KMT2A PTD by utilizing computational algorithms (Fig 3). We
suspect that patients with CNVs in genes associated with a worse prognosis, such as TP53,
might also benefit from our assay, the results from which could potential help in reconsidering
prognostic stratification and modifying treatment.
Recycling “garbage” data using CopywriteR was another innovative approach [15].
Sequence reads outside target regions have previously been discarded from mutation analysis;
however, reanalyzing off-target data could give us a complete view of genome wide copy num-
ber status. With this chromosomal CNV analysis, we could identify patients with cryptic losses
or gains that were missed by conventional cytogenetics. The analysis could not detect balanced
translocations due to an inherent drawback of signal ratio-based methods, as also seen in chro-
mosomal microarrays.
Table 5. Germline mutations identified in patients with AML and MPN.
ID Disease Age/
Sex
Gene† cDNA Amino acid Allele
frequency
Associated disease Inheritance
pattern
BM, day
28
P5� AML 62/M ATM c.5288_5289insGA p.Tyr1763� 0.52 Ataxia-telangiectasia AR CR
P81� AML 3/M BRCA2 c.8912delA p.Lys2971Serfs�5 0.5 Fanconi anemia, hereditary breast and
ovarian cancer
AR, AD ND
P75� AML 67/M DDX41 c.1496dupC p.Ala500Cysfs�9 0.47 Myeloproliferative/
lymphoproliferative neoplasm
AD PR
P99� AML 62/M DDX41 c.1496dupC p.Ala500Cysfs�9 0.46 Myeloproliferative/
lymphoproliferative neoplasm
AD CR
P30� AML 12/M FANCA c.1A>T p.Met1? 0.46 Fanconi anemia AR PR
P35� AML 26/F PALB2 c.1011_1015delACCAG p.Leu337Phefs�3 0.44 Fanconi anemia, hereditary breast and
ovarian cancer
AR, AD PR
P34� AML 17/M WRAP53 c.1564delG p.
Ala522Argfs�26
0.5 Dyskeratosis congenita AR PR
P37� AML 39/F WRAP53 c.1564delG p.
Ala522Argfs�26
0.54 Dyskeratosis congenita AR CR
P20 AML 25/F BLM c.320dupT p.
Leu107Phefs�36
0.49 Bloom syndrome AR CR
P111 MPN 83/F BRCA2 c.10150C>T p.Arg3384� 0.5 Fanconi anemia, hereditary breast and
ovarian cancer
AR, AD ND
P136 AML 40/M BRCA2 c.10150C>T p.Arg3384� 0.52 Fanconi anemia, hereditary breast and
ovarian cancer
AR, AD ND
P13 AML 41/F PALB2 Exon 8 deletion 0.5 Fanconi anemia, hereditary breast and
ovarian cancer
AR, AD CR
P66 MPN 72/M PALB2 c.1240C>T p.Arg414� 0.4 Fanconi anemia, hereditary breast and
ovarian cancer
AR, AD ND
P126 MPN 59/F RAD51 c.1dupA p.Met1? 0.49 Fanconi anemia AR ND
P69 MPN 54/M SBDS c.258+2T>C - 0.46 Shwachman-Diamond syndrome AR ND
AD, autosomal dominant; AR, autosomal recessive; BM, bone marrow; CR, complete remission; PR, partial remission; ND, not done
� Confirmed in germline samples
† For all genes, almost only germline mutations are thus far reported in myeloid neoplasms
https://doi.org/10.1371/journal.pone.0212228.t005
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Detecting gene fusion at the DNA level is an attractive option, considering the difficulties
in dealing with unstable RNA in conventional RT-PCR. For this purpose, we specifically
designed capture probes targeting intronic breakpoints of recurrent translocations and evalu-
ated various algorithms optimized for detecting large structural variations. The detection rate
of BreakDancer, a popular algorithm for translocation detection using paired-end mapping
method [8], was low. Delly, a combinatorial method combining paired-end mapping and
split-read [9], showed better capability in detecting known translocations, although it was not
perfect. This may be due to short read lengths and low read depths around certain breakpoints:
some intronic areas are difficult to capture due to the presence of repeat elements or variable
GC content. This was suggested by a previous study on a small subset of cases with ALK or
KMT2A translocations [33], and we also found a limitation for many recurrent translocations
in AML. Thus, one could conclude that short-read DNA sequencing cannot detect gene fusion
effectively, but can provide supplementary information to RNA testing.
By observing unexpectedly high frequencies, we could suggest that the existence of germline
predisposition mutations might have been underestimated and neglected thus far. This may be
due to the absence of available testing methods that could assess a number of responsible
genes before the NGS era. The previously reported DDX41 A500Cfs�9 mutation was found in
two cases [26,27]. The gene encodes an RNA helicase thought to function as a tumor suppres-
sor [34,35], and is known as one of the most frequently mutated predisposition gene in mye-
loid neoplasms [36]. The spectrum of germline mutations in DDX41 has revealed distinct
ethnically associated mutations, the most common of which (D149Gfs�2) has exclusively been
found in Caucasians [27,34,35], whereas A500Cfs�9 has only been documented in Asians
[26,27], suggesting the mutation derived from a founder mutation. Although cases with acqui-
sition of a somatic mutation in DDX41, in addition to germline mutation, have been reported
[34,35], no additional mutations in DDX41 were identified in our patients.
Patients with biallelic mutations in genes for MFS have ben shown to have a higher proba-
bility of acquiring hematologic cancers, such as acute leukemia [37,38]. However, the risk of
patients with monoallelic mutation in genes for MFS is largely unknown, although increased
risk for other solid cancers has been suggested for some genes [39–42]. Our data suggest that
monoallelic carriers also have an increased risk for hematologic malignancies, and this might
have different clinical implications as well. Although more data would be required to confirm
the consequence of these mutations, some patients showed poor treatment responses and mul-
tiple relapses. Having a germline mutation in cancer predisposition genes could lead to an
altered susceptibility to chemotherapy or a different bone marrow niche environment in stem
cell transplantation. Receiving stem cells from HLA-matched siblings that have a chance of
carrying the same germline mutation may be another issue of concern, as cases with donor cell
leukemia derived from a germline predisposition mutation in stem cell donors have been
reported [26,43].
More than half of the cases with germline predisposition mutations had mutations in genes
with increased risk for other cancers. Further genetic counseling for these patients and their
family members, along with the recommendation for cancer surveillance and a prevention
program, is an important issue. For example, patient P35 was a 26-year-old woman with AML
and was found to have a heterozygous PALB2 mutation. PALB2 is a BRCA2-interacting pro-
tein needed for the DNA repair function of BRCA2 [44], and the spectrum of cancers in
patients with the biallelic PALB2 mutation is very similar to those with biallelic BRCA2 muta-
tion [39]. Because monoallelic mutation of the PALB2 gene is associated with an approxi-
mately six-fold increased risk of breast cancer in female patients [39,45–47], National
Comprehensive Cancer Network guidelines recommend an annual mammogram and breast
magnetic resonance imaging for mutation carriers of PALB2 [48]. Accordingly, the patient
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and her family members received genetic counseling, and breast cancer surveillance was
planned after stem cell transplantation.
There are a few limitations in this study. As NGS testing results of matched germline sample
were not available, the possibility of incomplete filtering of germline variants cannot be elimi-
nated. Low capture efficiency is another limitation that needs to be improved.
In conclusion, we demonstrated that NGS testing, as a single assay, can be a good supple-
ment for a number of conventional molecular and cytogenetic tests through careful probe
design and comprehensive bioinformatics analyses. Furthermore, we found a high frequency
of germline mutations in germline predisposition genes in myeloid neoplasms, which suggests
a high implication of germline predisposition categories in the new WHO classification.
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